No Data
China Red Medical (300981.SZ): The main customers of the Safety Infusion Division products are currently in the domestic market.
On July 30th, gelunhui, 中红医疗(300981.SZ), stated on the investor interaction platform that the company's safety infusion business unit mainly serves the domestic market, and is not greatly affected by the above-mentioned additional tariffs. The main measures taken by the company regarding rubber glove tariffs include: 1. Expanding markets - actively exploring non-U.S. markets, improving market share in other regions. Marketing methods are used to promote the independent brand, vigorously expand the domestic market, and diversify market risks; 2. Reducing costs, promoting digital construction, reducing energ 南湖区南都村卫生室y consumption, and strengthening cost advantages; 3.布.
China Red Medical (300981.SZ): Kolon Medical Instruments obtains the registration certificate for one-time use venous indwelling needle medical instruments.
China Red Medical (300981.SZ) announced that its subsidiary, Jiangxi Kailuan Medical Instrument Manufacturing Co., Ltd. (hereinafter referred to as "...")
Zhonghong Medical (300981.SZ) plans to distribute 5 yuan per 10 shares on June 27th, ex-right and ex-dividend.
Zhonghong Medical (300981.SZ) announced that its annual equity distribution plan for 2023 is to distribute RMB 5.00 in cash (including tax) per 10 shares to all shareholders. The ex-rights and ex-dividend date is June 27, 2024.
Zhonghong Medical (300981.SZ): share buyback completed, a total of 8,426,000 shares were repurchased with a total expenditure of 10,025,900 yuan.
On June 14th, Gelonhui reported that Zhonghong Medical (300981.SZ) announced that the actual repurchase period of the company was from March 15, 2024 to June 13, 2024. The company used its own funds through a repurchase special securities account to accumulate repurchased shares in a centralized bidding method, with a total quantity of 842,555 shares, accounting for 0.2160% of the total share capital of the company. The highest fill price was 13.00 yuan/share, the lowest fill price was 10.35 yuan/share, and the total amount paid was 10.0259 million yuan (excluding trading fees). As of the disclosure date of the announcement, the company's share repurchase plan for this time has been fully implemented.
Returns On Capital Signal Tricky Times Ahead For Zhonghong Pulin Medical Products (SZSE:300981)
Zhonghong Healthcare (300981.SZ) announced its 2023 annual results, with a net loss of 131 million yuan, a year-on-year profit to loss
Zhonghong Healthcare (300981.SZ) released the 2023 annual results report. The company achieved operating income during the reporting period...
Investors Don't See Light At End Of Zhonghong Pulin Medical Products Co., Ltd.'s (SZSE:300981) TunnelNo Data
